Biostatistics Core Facilities/Collaborative Research
Biostatistics Cores generally provide support in the areas of data management, quality control, and data analysis to large medical center projects. A typical core develops the data entry system, checks the data for quality, produces reports for the P.I. and carries out analysis of the data. The core also assists the P.I. in the design of the trial and the protocol development.
Recent/current major Biostatistics Core Facilities supported by the Division of Biostatistics are:
- Research Design and Biostatistics Group for the Institute for Clinical and Translation Studies. (J. Philip Miller, Core Director, B. Evanoff, P.I.) Support ICTS members with design and protocol development, and develop methodology to enhance translational research. RDBG Website»
- Washington University Spotrias Center – Core D
(J. Philip Miller, Core Director, C. Derdeyn, P.I.) The Biostatistics Core will be responsible for the study design, data management system and the statistical analysis of the projects
- Alzheimer’s Disease Research Center – Biostatistics and Data Management Core – ADRC (Chengjie Xiong, Core Leader, J. Morris, P.I.) – Alzheimer’s Disease Research Center. Data management and analysis for over 20 years of longitudinal data. Affiliated projects explore the neuropathologic, behavioral, and genetic aspects of AD and other dementia.
- Healthy Aging and Senile Dementia – HASD
(Chengjie Xiong, Core Leader, J. Morris, P.I. ) – Healthy Aging and Senile Dementia. Study of clinical and biomedical correlates of the clinical course of Dementia of the Alzheimer’s Type (DAT) in comparison with healthy aging.
- Dominantly Inherited Alzheimer’s Network – Biostatistics Core
(Chengjie Xiong, Core Leader, J. Morris, P.I.) The Biostatistics core will bridge the transition from the DIAN databases to the analysis of the longitudinal data within, between, and among the various data domains.
- Antecedent Biomarkers for AD: The Adult Children Study
(Chengjie Xiong, Core Leader, J. Morris, P.I.) Because preclinical AD is asymptomatic, antecedent biological markers, neuroimaging measures, or other indicators need to be developed for its antemortem identification.